FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318447269> ?p ?o ?g. }

• W4318447269 endingPage "e13294" @default.
• W4318447269 startingPage "e13294" @default.
• W4318447269 abstract "PurposeThe purpose of this study was to investigate the correlation between S100 calcium binding protein A9 (S100A9), tumour glycolysis and tumour infiltrating lymphocytes (TIL) in human epidermal growth factor receptor 2 (HER2) - positive breast cancer (BRCA).Materials and methodsA total of 667 BRCA patients in Xiangya Hospital of Central South University were enrolled in this study. Haematoxylin and eosin (H&E) staining were used to count TIN in tissues. Human breast cancer cell lines (SK-BR-3 cells and BT474 cells) were transfected with S100A9 specific small interfering RNA (siRNA). The expressions of S100A9, glycolytic enzymes and lymphocyte markers were detected by immunohistochemistry (IHC) staining, Western blot and immunofluorescence. Lactate production, glucose consumption and the extracellular acidification rate (ECAR) were detected to assess glycolysis activity.ResultsS100A9 was significantly overexpressed in HER2+ cases. The expressions of phosphoglycerol kinase 1 (PGK1), lactate dehydrogenase A (LDHA) and enolase α (ENO1) were significantly up-regulated in S100A9 dominant tissues. The expressions of PGK1, LDHA and ENO1 detected in S100A9 silenced cell lines were significantly down-regulated. Moreover, S100A9 silencing significantly altered lactate production, glucose uptake and ECAR levels in HER2+ cell lines. Co-expression of S100A9 and c-Myc was detected in HER2+ tissues. The absence of S100A9 greatly hindered β-catenin expression in cell lines, which later induced the phosphorylation of c-Myc.The amount of TILs in cases with abundant S100A9 and LDHA was much greater than in cases with low S100A9 levels and poorer LDHA. TIL deficiency and elevated S100A9 intensity are factors affecting the survival rate of HER2+ BRCA cases.ConclusionsS100A9 overexpression upregulated the glycolysis activity of tumour cells through the c-Myc-related pathway, suppressing lymphocyte infiltration in the tumour stroma, affecting the efficacy of immune regulation and long-term survival of patients." @default.
• W4318447269 created "2023-01-30" @default.
• W4318447269 creator A5015786198 @default.
• W4318447269 creator A5033291987 @default.
• W4318447269 creator A5039857643 @default.
• W4318447269 date "2023-02-01" @default.
• W4318447269 modified "2023-10-18" @default.
• W4318447269 title "S100A9 promotes glycolytic activity in HER2-positive breast cancer to induce immunosuppression in the tumour microenvironment" @default.
• W4318447269 cites W1601678753 @default.
• W4318447269 cites W1987326983 @default.
• W4318447269 cites W1993340690 @default.
• W4318447269 cites W1994973292 @default.
• W4318447269 cites W2016655217 @default.
• W4318447269 cites W2017525816 @default.
• W4318447269 cites W2049319639 @default.
• W4318447269 cites W2074873270 @default.
• W4318447269 cites W2090861 @default.
• W4318447269 cites W2092627144 @default.
• W4318447269 cites W2096442461 @default.
• W4318447269 cites W2100039832 @default.
• W4318447269 cites W2108666460 @default.
• W4318447269 cites W2109621782 @default.
• W4318447269 cites W2117692326 @default.
• W4318447269 cites W2120431466 @default.
• W4318447269 cites W2123734813 @default.
• W4318447269 cites W2133105825 @default.
• W4318447269 cites W2145648359 @default.
• W4318447269 cites W2149106868 @default.
• W4318447269 cites W2160143217 @default.
• W4318447269 cites W2172697812 @default.
• W4318447269 cites W2183798533 @default.
• W4318447269 cites W2271190552 @default.
• W4318447269 cites W2281848173 @default.
• W4318447269 cites W2291579888 @default.
• W4318447269 cites W2322598518 @default.
• W4318447269 cites W2341529963 @default.
• W4318447269 cites W2407131888 @default.
• W4318447269 cites W2431653148 @default.
• W4318447269 cites W2466558384 @default.
• W4318447269 cites W2519020116 @default.
• W4318447269 cites W2530814271 @default.
• W4318447269 cites W2567947578 @default.
• W4318447269 cites W2588245864 @default.
• W4318447269 cites W2594575075 @default.
• W4318447269 cites W2742368813 @default.
• W4318447269 cites W2795915709 @default.
• W4318447269 cites W2809907394 @default.
• W4318447269 cites W2900073349 @default.
• W4318447269 cites W2901951820 @default.
• W4318447269 cites W2935724442 @default.
• W4318447269 cites W2942800275 @default.
• W4318447269 cites W2969535179 @default.
• W4318447269 cites W2972160826 @default.
• W4318447269 cites W3147130602 @default.
• W4318447269 cites W3150329092 @default.
• W4318447269 cites W3157713440 @default.
• W4318447269 cites W3212606565 @default.
• W4318447269 cites W4223452958 @default.
• W4318447269 cites W4231693644 @default.
• W4318447269 doi "https://doi.org/10.1016/j.heliyon.2023.e13294" @default.
• W4318447269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36755606" @default.
• W4318447269 hasPublicationYear "2023" @default.
• W4318447269 type Work @default.
• W4318447269 citedByCount "1" @default.
• W4318447269 countsByYear W43184472692023 @default.
• W4318447269 crossrefType "journal-article" @default.
• W4318447269 hasAuthorship W4318447269A5015786198 @default.
• W4318447269 hasAuthorship W4318447269A5033291987 @default.
• W4318447269 hasAuthorship W4318447269A5039857643 @default.
• W4318447269 hasBestOaLocation W43184472691 @default.
• W4318447269 hasConcept C134018914 @default.
• W4318447269 hasConcept C153911025 @default.
• W4318447269 hasConcept C181199279 @default.
• W4318447269 hasConcept C20251656 @default.
• W4318447269 hasConcept C203014093 @default.
• W4318447269 hasConcept C2776307749 @default.
• W4318447269 hasConcept C2776914184 @default.
• W4318447269 hasConcept C2777318727 @default.
• W4318447269 hasConcept C2910680157 @default.
• W4318447269 hasConcept C502942594 @default.
• W4318447269 hasConcept C55493867 @default.
• W4318447269 hasConcept C55885012 @default.
• W4318447269 hasConcept C62231903 @default.
• W4318447269 hasConcept C86803240 @default.
• W4318447269 hasConceptScore W4318447269C134018914 @default.
• W4318447269 hasConceptScore W4318447269C153911025 @default.
• W4318447269 hasConceptScore W4318447269C181199279 @default.
• W4318447269 hasConceptScore W4318447269C20251656 @default.
• W4318447269 hasConceptScore W4318447269C203014093 @default.
• W4318447269 hasConceptScore W4318447269C2776307749 @default.
• W4318447269 hasConceptScore W4318447269C2776914184 @default.
• W4318447269 hasConceptScore W4318447269C2777318727 @default.
• W4318447269 hasConceptScore W4318447269C2910680157 @default.
• W4318447269 hasConceptScore W4318447269C502942594 @default.
• W4318447269 hasConceptScore W4318447269C55493867 @default.
• W4318447269 hasConceptScore W4318447269C55885012 @default.
• W4318447269 hasConceptScore W4318447269C62231903 @default.
• W4318447269 hasConceptScore W4318447269C86803240 @default.

• next